Literature DB >> 19521310

Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors.

A Riaz1, R J Lewandowski, L Kulik, R Salem.   

Abstract

Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere for radioembolization in the management of liver tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521310

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  3 in total

1.  Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.

Authors:  Andrea M Abbott; Matthew P Doepker; Youngchul Kim; Matthew C Perez; Cassandra Gandle; Kerry L Thomas; Junsung Choi; Ravi Shridhar; Jonathan S Zager
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

Review 2.  Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors.

Authors:  Andrew Kuei; Sammy Saab; Sung-Ki Cho; Stephen T Kee; Edward Wolfgang Lee
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  [Experimental study of CT guided ³²P-CP-PLLA microparticle implantation in the treatment of rabbit VX2 lung tumor].

Authors:  Donghui Pan; Min Yang; Yuping Xu; Lizhen Wang; Lu Liu; Peilin Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.